Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00162669
Status:
UNKNOWN
Last Update Posted:
2006-09-08
First Post:
2005-09-08
Brief Title:
Bevacizumab in Advanced Hepatocellular Carcinoma
Sponsor:
Gustave Roussy Cancer Campus Grand Paris
Organization:
Gustave Roussy Cancer Campus Grand Paris
Study Overview
Official Title:
Phase II Study Evaluating the Efficacy of Bevacizumab Avastin in Hepatocellular Carcinoma Not Amenable to Curative Treatment
Status:
UNKNOWN
Status Verified Date:
2006-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary liver cancer hepatocellular carcinoma is the fifth most common malignant disorder with an increasing incidence in Europe and the USA as a result of the high prevalence of hepatitis C Most patients are not suitable for potentially curative treatment There is no standard palliative treatment for patients with advanced hepatocellular carcinoma HCC as no drug has been demonstrated to be efficient in this disease in terms of survival The use of anti-vascular agents might be a promising approach in view of the highly vascular nature of this tumor The aim of this phase II trial is to evaluate the potential benefit of bevacizumab in terms of disease control rate progression-free and overall survival in adult patients with advanced primary liver cancer Bevacizumab is an angiogenesis inhibitor already successfully used in patients with colorectal and renal cancers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HCC-Avastin | None | None | None |